Surprisingly, IDH mutant status does not predict response to procarbazine, lomustine, and vincristine in patients with anaplastic oligodendroglioma providing insights into the possible inactivation of MGMT because of CIMP induced by IDH mutations. The gene discussed is IDH2; the disease is anaplastic oligodendroglioma.